Suspension of the de minimis administrative exemption for imports $800 or less

The suspension of the de minimis exemption, which previously allowed imports valued under $800 to enter the U.S. duty-free and with minimal customs scrutiny, could significantly raise costs and slow delivery for consumers who rely on low-cost imports, including affordable prescription drugs from Canadian pharmacies. This change matters to both consumers seeking savings and businesses that depend on streamlined cross-border shipping.

• The de minimis exemption for imports valued at $800 or less has been suspended, ending simplified low-value import processing.
• This change could increase costs and complicate access to affordable goods, including prescription drugs from licensed Canadian pharmacies.
• Advocacy groups like CPPI are mobilizing public support to protect consumers' ability to purchase cheaper medications from abroad.